Labcorp Holdings Inc. LH SPX

Healthcare · Diagnostics & Research · United States

https://www.labcorp.com

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Market & Price

Market Cap

$21.32B

Current Price

$260.06

High / Low (52W)

$288.63 / $240.50

Beta

0.88

Valuation

Stock P/E

23.03

Industry PE

23.65

Forward P/E

13.38

PEG Ratio

1.10

Book Value

$104.86

Price to Book

2.48

P/S

1.51

EV/EBITDA

12.28

Dividend Yield

1.11%

Profitability & Returns

ROCE

8.55%

ROE

11.05%

ROA

5.31%

Profit Margin

6.66%

Op Margin

10.95%

EPS (Latest Qtr)

$3.35

EPS (TTM)

$11.29

Balance Sheet & Liquidity

Debt/Equity

0.83

Quick Ratio

1.30

Current Ratio

1.73

Debt

$7.29B

Total Assets

$18.39B

Current Assets

$4.02B

Working Capital

$1.20B

Ownership

Promoter Holding

0.35%

Chg in Prom Hold

FII / Inst Holding

100.40%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$27.66B

Total Revenue (TTM)

$14.14B

EBITDA

$2.25B

Free Cash Flow

$1.14B

Operating Cash Flow

$1.81B

Shares Outstanding

82.00M

Gross Margin

28.83%

Payout Ratio

25.51%

Growth (CAGR)

Revenue 5Y

5.55%

Profit 5Y

-11.84%

Revenue (YoY)

5.80%

Earnings (YoY)

32.90%

PROS

Generates positive free cash flow.

CONS

Earnings shrank at -11.8% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LH Labcorp Holdings Inc. SPX	260.06	23.03	$21.32B	1.11%	8.55%	11.05%	5.55%	-11.84%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	2.27B	2.32B	-	9.64B	2.43B	2.41B	-	2.41B	2.53B	2.62B	2.74B	2.85B	2.87B	2.83B	2.79B	2.79B	2.88B	2.93B	2.95B	2.82B	2.77B	3.90B	4.16B	3.84B	4.06B	3.90B	2.92B	2.87B	3.04B	3.03B	3.06B	3.18B	3.22B	-	-	3.35B	3.53B	3.56B	3.52B	3.54B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.40B	2.48B	2.54B	2.52B	2.52B
Gross Profit	772.60M	764.90M	740.70M	777.30M	826.80M	788.40M	788.00M	712.50M	778.00M	784.20M	817.10M	779.00M	835.10M	789.90M	772.40M	789.70M	824.80M	817.30M	820.70M	728.00M	760.50M	1.56B	1.60B	1.26B	1.39B	1.23B	942.50M	886.20M	850.10M	842.20M	851.20M	897.30M	926.40M	-	-	948.00M	1.05B	1.03B	993.20M	1.01B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	615.60M	647.60M	621.90M	611.20M	626.60M
Operating Income	323.30M	308.10M	-	299.50M	365.50M	324.00M	-	318.10M	329.80M	326.70M	330.60M	305.40M	369.20M	343.40M	307.70M	318.20M	335.70M	339.90M	336.40M	-192.60M	297.70M	1.05B	1.06B	704.10M	766.90M	687.90M	428.80M	374.00M	329.80M	266.30M	252.30M	321.30M	294.80M	-	-	332.40M	398.60M	403.20M	382.00M	387.20M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	498.00M	532.10M	564.00M	418.60M	548.10M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.00M	57.10M	56.00M	55.00M	55.10M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	275.20M	304.70M	337.00M	190.60M	319.70M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62.20M	66.40M	75.50M	25.70M	41.70M
Net Income	169.90M	154.70M	110.00M	164.10M	204.10M	179.50M	184.40M	183.00M	184.80M	171.50M	687.80M	173.20M	233.80M	318.80M	157.90M	185.60M	190.40M	-317.20M	227.10M	-317.20M	231.60M	703.40M	769.60M	467.40M	587.30M	491.60M	358.60M	352.80M	212.90M	188.90M	183.30M	228.00M	205.30M	-	-	212.80M	237.90M	261.10M	164.70M	277.80M
Diluted EPS	1.66	1.51	1.07	1.58	1.96	1.71	1.75	1.75	1.78	1.65	6.63	1.67	2.27	3.10	1.56	1.86	1.93	2.25	2.32	-3.27	2.37	7.17	7.82	4.76	6.05	5.23	3.87	3.90	2.39	2.12	2.11	2.69	2.43	-	-	2.52	2.84	3.12	1.98	3.35

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	5.81B	6.01B	8.68B	9.55B	10.31B	11.33B	11.55B	13.98B	13.14B	11.86B	12.16B	13.01B	13.95B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.15B	8.80B	9.38B	9.94B
Gross Profit	1.69B	1.87B	1.97B	2.10B	2.27B	2.25B	2.22B	2.20B	2.90B	2.85B	3.09B	3.18B	3.25B	4.95B	4.99B	3.71B	3.36B	3.62B	4.01B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.96B	2.24B	2.49B	2.50B
Operating Income	777.00M	842.90M	935.90M	978.80M	948.40M	1.02B	990.90M	910.40M	996.80M	1.27B	1.31B	1.33B	1.33B	2.45B	3.05B	1.75B	1.12B	1.14B	1.52B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.95B	1.35B	1.81B	2.01B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	179.80M	199.60M	208.30M	224.10M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.24B	568.90M	959.50M	1.11B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	233.90M	188.50M	212.40M	229.80M
Net Income	476.80M	464.50M	543.30M	558.20M	519.70M	583.10M	573.80M	511.20M	437.60M	711.80M	1.23B	883.70M	823.80M	1.56B	2.38B	1.28B	418.00M	746.00M	876.50M
Diluted EPS	3.93	4.16	4.98	5.29	5.11	5.99	6.25	5.91	4.35	6.82	11.81	8.61	8.35	15.88	24.39	13.97	4.77	8.84	10.46

Compounded Sales Growth

5 Years:	5.55%
1 Year:	5.80%

Compounded Profit Growth

5 Years:	-11.84%
1 Year:	32.90%

Stock Price Performance

1 Year:	+5.56%
6 Months:	-2.85%
3 Months:	-9.80%
1 Month:	+1.41%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	4.67B	4.84B	6.19B	6.11B	6.79B	6.97B	7.30B	14.10B	14.25B	16.67B	16.19B	18.05B	20.07B	-	20.16B	16.73B	18.38B	18.39B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.62B	3.77B	4.81B	4.02B
Cash & Equivalents	51.50M	56.40M	219.70M	148.50M	159.30M	159.30M	404.00M	404.00M	580.00M	716.40M	433.60M	316.60M	426.80M	337.50M	1.32B	-	320.60M	536.80M	1.52B	532.30M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	470.60M	474.60M	493.20M	534.70M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.79B	1.91B	1.94B	2.10B
Total Liabilities	-	-	2.86B	2.73B	3.70B	3.59B	4.06B	4.46B	4.46B	9.14B	8.73B	9.85B	9.19B	10.46B	10.61B	-	10.04B	8.83B	10.31B	9.76B
Current Liabilities	-	-	546.90M	1.02B	1.12B	732.60M	1.03B	735.70M	976.30M	1.70B	1.83B	2.19B	1.88B	2.66B	3.08B	-	3.08B	3.23B	3.33B	2.82B
Long Term Debt	-	-	1.60B	977.20M	1.83B	2.09B	2.17B	2.89B	2.68B	5.94B	5.30B	6.34B	5.99B	5.79B	5.42B	-	5.04B	4.05B	5.33B	5.08B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.25B	5.95B	7.27B	6.53B
Total Equity	1.98B	1.73B	1.69B	2.11B	2.47B	2.50B	4.95B	2.49B	2.82B	4.95B	5.52B	6.80B	7.05B	7.64B	9.44B	-	10.10B	7.88B	8.05B	8.62B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88.20M	83.90M	83.40M	82.20M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	709.70M	780.90M	862.40M	883.60M	855.60M	841.40M	818.70M	739.00M	982.40M	1.20B	1.50B	1.31B	1.44B	2.14B	-	1.96B	1.33B	1.59B	1.64B
Investing Cash Flow	-341.50M	-396.00M	-334.00M	-1.32B	-280.30M	-534.20M	-359.60M	-350.10M	-3.99B	-795.70M	-2.23B	206.70M	-1.28B	-643.20M	-	-1.65B	-1.17B	-1.37B	-1.19B
Financing Cash Flow	-363.70M	-218.50M	-600.90M	515.30M	-645.00M	-800.00K	-518.30M	-200.60M	3.18B	-671.00M	593.20M	-1.39B	-252.70M	-517.40M	-	-1.32B	-59.30M	779.90M	-1.46B
Capital Expenditure	-142.60M	-156.70M	-114.70M	-126.10M	-145.70M	-173.80M	-202.20M	-203.50M	-255.80M	-278.90M	-312.90M	-379.80M	-400.20M	-381.70M	-	-429.30M	-453.60M	-489.90M	-434.50M
Free Cash Flow	567.10M	624.20M	747.70M	757.50M	709.90M	667.60M	616.50M	535.50M	726.60M	918.20M	1.19B	925.60M	1.04B	1.75B	-	1.53B	874.10M	1.10B	1.21B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.13B	96.90M	998.90M	-1.01B
Share Buybacks	921.20M	333.60M	273.00M	338.10M	643.90M	516.50M	1.02B	269.00M	0	43.90M	338.10M	700.00M	450.00M	100.00M	1.67B	1.10B	1.00B	250.10M	450.00M
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	195.20M	254.00M	243.10M	240.70M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	38.3%	36.6%	33.4%	29.9%	30.0%	28.0%	28.1%	35.4%	38.0%	31.3%	27.7%	27.9%	28.8%
Operating Margin %	-	-	-	-	-	-	17.1%	15.1%	11.5%	13.3%	12.7%	11.7%	11.5%	17.5%	23.2%	14.8%	9.2%	8.7%	10.9%
Net Margin %	-	-	-	-	-	-	9.9%	8.5%	5.0%	7.5%	11.9%	7.8%	7.1%	11.1%	18.1%	10.8%	3.4%	5.7%	6.3%
ROE %	27.6%	27.5%	25.8%	22.6%	20.8%	11.8%	23.0%	18.1%	8.8%	12.9%	18.0%	12.5%	10.8%	16.5%	-	12.7%	5.3%	9.3%	10.2%
ROCE %	-	20.4%	24.5%	19.3%	17.6%	17.7%	15.9%	14.4%	8.0%	10.2%	9.0%	9.3%	8.6%	14.4%	-	10.3%	8.3%	7.6%	9.7%

Shareholding Pattern

Insiders

0.35%

Institutions

100.40%

Public Float

100.76%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	7.86%	6.44M	$1.68B
2	Vanguard Capital Management LLC	6.56%	5.38M	$1.40B
3	Victory Capital Management Inc.	5.64%	4.63M	$1.20B
4	State Street Corporation	4.71%	3.86M	$1.00B
5	Vanguard Portfolio Management LLC	4.49%	3.68M	$957.19M
6	Boston Partners	2.89%	2.37M	$616.03M
7	Allspring Global Investments Holdings, LLC	2.72%	2.23M	$579.01M
8	Geode Capital Management, LLC	2.67%	2.19M	$568.48M
9	Select Equity Group LP	2.65%	2.17M	$565.57M
10	JPMORGAN CHASE & CO	1.87%	1.53M	$398.60M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LH

No recent headlines available.

LH · Healthcare